KZR NASDAQ
South San Francisco, CA 94080
US
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wallace Courtney | D-Return | 3,500 | $26.40 | 2026-05-11 |
| Wallace Courtney | D-Return | 5,000 | $6.70 | 2026-05-11 |
| Wallace Courtney | D-Return | 5,000 | $4.46 | 2026-05-11 |
| Wallace Courtney | D-Return | 2,600 | $22.80 | 2026-05-11 |
| Schiller Mark C. | U-Tender | 2,739 | $6.96 | 2026-05-11 |